[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors

Med. Chem. Commun.
2010.0

Abstract

Investigating a series of anilinoquinazoline derivatives substituted by carbamic acid esters, we have established the importance of the carbamate functional group and the substitution on the arylamino ring by a donor/acceptor group such as halide or methyl. All the newly-synthesized compounds described were evaluated for both their in vitro EGFR and VEGFR-2 kinase inhibition and antiproliferative activities against various cancer cells. These novel compounds were effective tyrosine kinase inhibitors (TKIs) for these two enzymes with in vitro IC50 values in the submicromolar range, but showed a moderated inhibitory activity on cancer cells. Modification of the ether linkage at the 6 or 7- position of the quinazoline core with a basic or aliphatic side chain (70–80) was investigated and it was demonstrated that introduction of aminoalkyl substituents such as morpholinoethoxy is a key modification that increases antiproliferative activity.

Knowledge Graph

Similar Paper

[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors
Med. Chem. Commun. 2010.0
Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0
Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors
European Journal of Medicinal Chemistry 2016.0
Enhancement of EGFR tyrosine kinase inhibition by C–C multiple bonds-containing anilinoquinazolines
Bioorganic & Medicinal Chemistry 2010.0
Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2
Bioorganic & Medicinal Chemistry 2007.0
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2006.0
Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments
Bioorganic & Medicinal Chemistry Letters 2021.0
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity
European Journal of Medicinal Chemistry 2015.0
Novel 4-arylaminoquinazoline derivatives with ( E )-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells
European Journal of Medicinal Chemistry 2017.0
Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors
Bioorganic & Medicinal Chemistry Letters 2017.0